Unusual adverse event with vandetanib in metastatic medullary thyroid cancer

Journal of Clinical Oncology

Volumn 30, Issue 2, 2012, Pages

  Duplomb, Sophie ^a   Benoit, Amandine ^b   Mechtouff Cimarelli, Laura ^b   Cho, Tae Hee ^b   Derbel, Olfa ^a   Peix, Jean Louis ^c   De La Fouchardière, Christelle ^a  

^a CENTRE LÉON BÉRARD   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCIUM; DULOXETINE; NIMODIPINE; VANDETANIB; VITAMIN D;

ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CERVICAL LYMPH NODE; CHEMOEMBOLIZATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; SUBARACHNOID HEMORRHAGE; THUNDERCLAP HEADACHE; THYROID CANCER; THYROID MASS; THYROIDECTOMY;

HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PIPERIDINES; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84855590684     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.2796     Document Type: Article

References (10)

1. Ball DW: Management of medullary thyroid cancer. Minerva Endocrinol 36:87-98, 2011
2. Wells SA Jr, Robinson BG, Gagel RF, et al: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol [epub online ahead of print on October 24, 2011]
3. Ducros A, Boukobza M, Porcher R, et al: The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome: A prospective series of 67 patients. Brain 130:3091-3101, 2007 (Pubitemid 350209073)
4. Nebeker JR, Barach P, Samore MH: Clarifying adverse drug events: A clinician's guide to terminology, documentation, and reporting. Ann Intern Med 140:795-801, 2004 (Pubitemid 38623529)
5. Broniscer A, Baker JN, Tagen M, et al: Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 28:4762-4768, 2010
6. Bartynski WS: Posterior reversible encephalopathy syndrome, part 2: Controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 29:1043-1049, 2008
7. Heymach JV, Paz-Ares L, De Braud F, et al: Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26:5407-5415, 2008
8. Natale RB, Thongprasert S, Greco FA, et al: Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29:1059-1066, 2011
9. Robinson BG, Paz-Ares L, Krebs A, et al: Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95:2664-2671, 2010
10. Wells SA, Gosnell JE, Gagel RF, et al: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772, 2010